INTRODUCTION {#s1}
============

Usually, fertility-sparing surgery (FSS) has been acceptably chosen for young patients with an ovarian-confined / capsulated / well-differentiated epithelial ovarian cancer (EOC), as well as those with borderline, germ cell, and stromal tumor. Previous studies reported FSS as an alternative therapy to radical surgery in selected patients of child-bearing age, when the oncological outcome of patients treated with FSS was determined to be equivalent to that of patients treated with radical surgery \[[@R1]--[@R6]\]. However, evidence supporting the safety and effectiveness of conservative surgery is limited, and a standard indication for FSS remains controversial even for EOC, because randomized clinical trials are difficult to conduct due to ethical issues.

Mature cystic teratoma (MCT) is a common asymptomatic disease in women of child-bearing age, comprising up to a quarter of all ovarian tumors, with an incidence of 1.2-14.2 cases per 100000 per year \[[@R7]--[@R10]\]. MCT normally contains mature tissues from all three germ-cell layers (ectoderm, mesoderm and endoderm). It has been reported that malignant transformation of MCT (MT-MCT) usually occurs only in approximately 1-3% of MCT cases \[[@R9]\]. The most common malignant histological type of MT-MCT is squamous cell carcinoma (SCC) originating from ectodermal tissue, which accounts for 80-90%, but adenocarcinomas, carcinoid tumors and melanomas have also been reported infrequently \[[@R9], [@R11]--[@R13]\]. Although MT-MCT is normally diagnosed at menopausal age, our colleagues reported at least one fourth of MT-MCT actually occurs in reproductive-age women \[[@R14]\]. Due to its rarity, MT-MCT is not even independently categorized as a type of histology into the National Comprehensive Cancer Network Guidelines 2017. To our best knowledge, there has been no study assessing the applicability of FSS for MT-MCT.

This study was aimed to overview the oncologic outcome patients in our experience and explore the eligibility of FSS for MT-MCT. An insight into the valid management strategies for MT-MCT in child-bearing age was proposed.

RESULTS {#s2}
=======

From 1986 to 2016, a total of 62 patients with MT-MCT were registered to this study. The clinicopathological characteristics of these patients are summarized in Table [1](#T1){ref-type="table"}. The median follow-up time and the median age of patients were 38.0 (2.0-227.9) months and 54 (17-82) years old. Of a total of 62 patients, 38 patients had stage I disease, 5 had stage II disease, 17 had stage III, and 2 had stage IV, respectively. A total of 17 (27.4%) patients were treated with conservative surgery instead of radical surgery. Squamous cell carcinoma accounted for more than 90% of our cases. We first overviewed oncologic outcome of patients in our experience. Kaplan-Meier curves of OS and DFS, demonstrating demonstrated both 5-year OS and DFS were 64%. In order to identify possible prognostic factors affecting OS and DFS, univariate and multivariate analyses were performed (Table [2](#T2){ref-type="table"}). Age, surgical procedures, residual tumor at initial surgery, adjuvant chemotherapy, SCC and CA125 did not influence OS or DFS in both univariate and multivariate analyses. Only FIGO stage was a significant prognostic factor for both OS and DFS in multivariate analyses (OS: HR: 6.58, 95% CI: 1.82-24.78, P =0.0048; DFS: HR: 5.59, 95% CI: 1.52-21.83, P =0.01). In fact, 5-year OS was as follows: stage I-II, 78%; stage III-IV, 32%. The prognosis of patients with early stage was much more favorable than in those with advanced stage, therefore FSS may be acceptable for patients with early stage MT-MCT who hope to preserve fertility.

###### Patient characteristics

                               n (%)
  ---------------------------- ------------
  Age, years                   
   median age (range)          54 (17-82)
   ≧60                         25 (40.3)
   45-59                       17 (27.4)
   \<45                        20 (32.3)
  Stage                        
   I                           38 (61.3)
    IA                         22
    IC                         16
   II                          5 (8.1)
    IIA                        1
    IIB                        2
    IIC                        2
   III                         17 (27.4)
    IIIB                       7
    IIIC                       10
   IV                          2 (3.2)
  Surgical Procedures          
   Radical surgery             45 (72.6)
    Complete surgery^\*^       15
    Incomplete surgery^\*\*^   30
   Conservative surgery        17 (27.4)
  Residual tumor               
   Yes                         53 (85.5)
   No                          9(14.5)
  Histology                    
   Squamous cell carcinoma     57 (91.9)
   Adenocarcinoma              3 (4.8)
   Adenosquamous carcinoma     1 (1.6)
   Malignant melanoma          1 (1.6)
  SCC (ng/dL)                  
   \< 2                        9 (14.5)
   ≧ 2                         31 (50.0)
   Unknown                     22 (35.5)
  CA125 (U/mL)                 
   \< 100                      45(72.6)
   ≧ 100                       15 (24.2)
   Unknown                     2 (3.2)
  Adjuvant Chemotherapy        
   Yes                         37 (59.7)
   No                          19 (30.6)
   Unknown                     6 (9.7)

Complete surgery^\*^ was defined as completion of all procedures in radical operation including total hysterectomy and bilateral salpingo-oophorectomy with peritoneal staging and lymphadenectomy. Incomplete surgery^\*\*^ was defined as completion of total hysterectomy and bilateral salpingo-oophorectomy.

###### Uni- and multivariate analyses of clinicopathologic parameters in relation to OS and DFS of patients

  Variable                                             Univariate   Multivariate                                  
  ---------------------------------------------------- ------------ -------------- ---------- ------ ------------ --------
  Overall survival                                                                                                
   Age (≧45 versus \<45)                               0.68         0.28-1.75      0.41       0.53   0.19-1.49    0.22
   Stage (III-IV versus I-II)                          6.14         2.50-15.9      \<0.0001   6.58   1.82-24.78   0.0048
   Surgical procedures (Conservative versus Radical)   0.41         0.10-1.24      0.12       0.75   0.13-3.30    0.71
   Residual tumor (Yes versus No)                      3.74         1.32-9.36      0.02       0.76   0.21-2.74    0.67
   SCC (≧2.0 versus \<2.0)(ng/dL)                      2.20         0.59-14.27     0.26       1.30   0.25-10.50   0.77
   ≧100 versus \<100)(U/mL)                            1.57         0.59-3.84      0.35       1.25   0.44-3.33    0.66
   Chemotherapy (Yes versus No)                        205          0.73-7.24      0.18       0.79   0.23-3.13    0.72
  Disease-free survival                                                                                           
   Age (≧45 versus \<45)                               0.69         0.29-1.78      0.43       0.57   0.20-1.63    0.29
   Stage (III-IV versus I-II)                          5.43         2.22-14.01     0.0002     5.59   1.52-21.83   0.01
   Surgical procedures (Conservative versus Radical)   0.43         0.10-1.30      0.14       0.86   0.16-3.75    0.84
   Residual tumor (Yes versus No)                      3.50         1.23-8.76      0.02       0.81   0.23-2.93    0.75
   SCC (≧2.0 versus \<2.0)(ng/dL)                      1.97         0.53-12.73     0.34       0.99   0.20-7.41    0.99
   ≧100 versus \<100)(U/mL)                            1.69         0.63-4.13      0.28       1.27   0.45-3.30    0.64
   Chemotherapy (Yes versus No)                        2.09         0.32-12.03     0.36       0.86   0.25-3.42    0.82

We subsequently explore the possibility of FSS in young patients with MT-MCT. The clinicopathological features of patients with early stage disease among group A, B, and C are summarized in Table [3](#T3){ref-type="table"}. Of seven patients in group A, five patients underwent unilateral salpingo-oophorectomy, and the other two patients received unilateral cystectomy. We selected FSS for the patient with stage II MT-MCT because they wished to preserve fertility regardless of our recommendation for radical surgery, which resulted in recurrence. Three patients treated with FSS underwent adjuvant chemotherapy. The clinical characteristics excluding surgical procedures were not statistically different among the three groups. Figure [1](#F1){ref-type="fig"} shows the Kaplan Meier curves for OS among three groups, and 5-year OS in the individual groups was as follows: group A, 83%; group B, 83%; and group C, 77%. No significant difference regarding long-term survival was found among these groups.

###### Clinicopathological features of early stage MT-MCT among group A, B, and C

                             Group A (n=7)   Group B (n=6)   Group C (n=30)   *P*-value
  -------------------------- --------------- --------------- ---------------- -----------
  Stage                                                                       0.2965
   I                         6               5               27               
    IA                       4               2               16               
    IC                       2               3               11               
   II                        1               1               3                
    IIA                      1               0               0                
    IIB                      0               0               2                
    IIC                      0               1               1                
  Surgical procedures                                                         0.0032
   Radical surgery           0               6               21               
    Complete surgery         0               4               7                
    Incomplete surgery       0               2               14               
   Conservative surgery      7               0               9                
  Histology                                                                   0.8416
   Squamous cell carcinoma   6               6               28               
   Adenocarcinoma            0               0               1                
   Adenosquamous carcinoma   1               0               1                
   Malignant melanoma        0               0               0                
  SCC (ng/dL)                                                                 0.8818
   \< 2                      2               1               5                
   ≧ 2                       2               3               15               
   Unknown                   3               2               10               
  CA125 (U/mL)                                                                0.35
   \< 100                    6               5               21               
   ≧ 100                     1               0               8                
   Unknown                   0               1               1                
  Adjuvant Chemotherapy                                                       0.8475
   Yes                       3               4               16               
   No                        3               2               12               
   Unknown                   1               0               2                

![Kaplan-Meier estimated OS of early stage MT-MCT patients divided into three groups: group A, patients who underwent FSS under 45 years old; group B, patients who underwent radical surgery under 45 years old; group C, patients over 46 years old](oncotarget-09-27564-g001){#F1}

With regard to obstetrical outcome after FSS, two patients gave birth to healthy children. One patient became pregnant and gave birth to a healthy child after FSS, and the other patient underwent unilateral cystectomy for MT-MCT at 16 weeks pregnant, and then had a baby by cesarean section.

All 25 MT-MCT patients treated with conservative surgery listed in Table [4](#T4){ref-type="table"} were derived from previous representative reports and our current study \[[@R15]--[@R24]\]. The median age of these patients was 31 years old (19-41). Only one patient with stage II disease in our study relapsed (3.8%) and died due to disease progression. Except for this patient, the other 25 patients had stage I disease. Eight out of 25 patients (32%) with stage I MT-MCT received adjuvant chemotherapy following FSS, including paclitaxel and cisplatin. With respect to surgical procedure, unilateral oophorectomy with or without omentectomy and lymphadenectomy were mainly performed as FSS.

###### Summary of clinical outcomes and fertility results of MT-MCT patients treated conservatively in our current study and previous reports

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case ID   Author           Age   Stage                           Primary Surgery                 Histology   Adjuvant Chemotherapy       Chemotherapy\    Status   Overall Survival\   Pregnancy\
                                                                                                                                           (course)                  (months)            outcome
  --------- ---------------- ----- ------------------------------- ------------------------------- ----------- --------------------------- ---------------- -------- ------------------- ------------
  1         Current report   41    IA                              RSO                             SCC         No                                           NED      226                 \-

  2         30               IA    RSO                             SCC                             No                                      NED              131      1 (NVD)             

  3         33               IA    RSO + App                       SCC                             Yes         PTX + CBDCA (3)             NED              60       \-                  

  4         40               IC    RSO                             SCC                             No                                      NED              24       \-                  

  5         38               IA    left cystectomy                 SCC                             Yes         PTX + CBDCA (3)             NED              10       \-                  

  6         31               IIA   RSO + left cystectomy + OM      SCC                             Yes         CDDP + 5FU (1)\             DOD              10       \-                  
                                                                                                               GEM + CBDCA (4) + Bev (3)                                                 

  7         30               IC    right cystectomy                AC                              NA                                      NED              11       1 (CS)              

  8         Tseng            31    IA                              USO                             SCC         \-                          \-               NED      51                  NA

  9         21               IA    USO                             SCC                             \-          \-                          NED              105      NA                  

  10        22               IA    LSO                             SCC                             \-          \-                          NED              121      NA                  

  11        34               IA    USO                             SCC                             \-          \-                          NED              91       NA                  

  12        Rim              19    IA                              LSO                             SCC         \-                          \-               NED      5                   NA

  13        36               IA    LSO                             SCC                             \-          \-                          NED              20       NA                  

  14        Arioz            31    IIA                             USO + OM + PLND + PALND + App   SCC         Yes                         PTX + CDDP (6)   NED      6                   NA

  15        Gainford         31    IA                              USO                             SCC         Yes                         CDDP + ETP (5)   NED      108                 NA

  16        21               IA    USO                             SCC                             \-          \-                          NED              12       NA                  

  17        27               IA    USO                             SCC                             \-          \-                          NED              48       NA                  

  18        28               IC    USO + PALND                     SCC                             Yes         CDDP + ETP (3)              NED              18       NA                  

  19        Sakuma           36    IA                              LSO                             SCC         \-                          \-               NED      72                  NA

  20        Budiman          41    IA                              RSO                             SCC         \-                          \-               NED      37                  1 (NVD)

  21        Chiang           32    IA                              RSO                             SCC         Yes                         BEP (6)          NED      104                 NA

  22        Yun              30    \-                              LSO + right cystectomy          SCC         \-                          \-               NED      60                  1 (NVD)

  23        Koc              28    IC                              LSO                             SCC         Yes                         PTX + CDDP (3)   NED      96                  NA

  24        35               IA    LSO                             SCC                             \-          \-                          NED              114      NA                  

  25        38               IA    LSO + PLND + PALND + OM + App   SCC                             \-          \-                          NED              96       NA                  
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: RSO: right salpingo-oophorectomy, App: appendectomy, USO: unilateral salpingo-oophorectomy, LSO: left salpingo-oophorectomy, OM: omentectomy, PLND: pelvic lymph node dissection, PALND: para-aortic lymph node dissection, SCC: squamous cell carcinoma, AC: adenocarcinoma, NA: not available, NED: no evidence of disease, DOD: died of disease, NVD: normal vaginal delivery, CS: cesarean section.

DISCUSSION {#s3}
==========

Preservation of reproductive function is strongly desired by patients with ovarian malignancy at child-bearing age. Previous reports analyzing the clinical outcomes of women who received the surgical procedure have revealed the possibility of preserving fertility in early stage EOC \[[@R2], [@R25]\]. Regarding MT-MCT, there is currently no study evaluating eligibility for FSS or proposing criteria for FSS. Our current study is the largest case series study to evaluate prognostic factors affecting long-term clinical outcome of patients with MT-MCT, and to propose recommended criteria for FSS for MT-MCT.

Preoperative diagnosis of MT-MCT is difficult, especially in early stages, thus MT-MCT is usually diagnosed by postoperative histopathological examination. Moreover, like other ovarian malignancies, it is reported that the prognosis of this disease depends on the stage at diagnosis \[[@R9]\]. A previous study on 37 patients with MT-MCT reported that the 5-year survival rates was 94.7% for stage I, 80.0% for stage II and 0% for stage III and stage IV, indicating that patients with the disease in FIGO stage I have a relatively good prognosis \[[@R26]\]. Indeed, the 5-year OS of our patients with early stage MT-MCT was more favorable than that of patients with advanced stage MT-MCT in the total population. The FIGO stage at diagnosis was the only determinant of survival outcome according to our multivariate analysis. We suggest that conservative surgery may acceptable only for patients with early stage disease, and should not be applied to patients with advanced stage, although it is difficult to correlate the prognosis of these patients with surgical procedures.

Compared with previous reports, 5-year OS and DFS of stage I MT-MCT in this study were likely to be equivalent with those of stage I EOC \[[@R3], [@R9], [@R26], [@R27]\]. On the other hand, the prognosis of stage II MT-MCT was poorer than that of stage I disease, as in previous stage II MT-MCT.

Optimal surgical procedures for MT-MCT are undefined, compared with those for EOC. According to the National Comprehensive Cancer Network Guidelines 2017, FSS including USO preserving the uterus and contralateral ovary may be considered for patients with apparent early-stage disease and/or good-risk tumors, including malignant germ cell tumors, who hope to preserve fertility, whereas complete staging surgery is recommended for patients not desiring fertility preservation \[[@R28]\]. However, there are no criteria regarding FSS for MT-MCT. To our best knowledge, there are only a few reports regarding FSS for patients of reproductive age with MT-MCT who desire future fertility. Gainford et al. reported that FSS may be a reasonable choice in selected patients with stage I disease, based on their experiences \[[@R18]\]. However, we think that the number of patients are too small-scale to draw a reliable conclusion with respect to validity of FSS. In this study, we presented the clinical outcomes of a total of 62 patients with MT-MCT, and our results demonstrated no correlation between prognosis and surgical procedure by both univariate and multivariate analyses. Furthermore, in our study, not only unilateral salpingo-oophorectomy but unilateral cystectomy was performed as FSS for stage I disease, with no relapse. MT-MCT is frequently diagnosed at postoperative histopathological examination even if the preoperative diagnosis was benign. Our results suggest that patients treated with unilateral cystectomy may not need to undergo additional radical surgery following primary surgery.

According to the comparison of the younger age group (≤45) with the older age group (\>45) in the univariate analysis, the survival differences in OS and DFS were not significant. Additionally, in the younger age group, 5-year OS and DFS of patients undergoing FSS were likely to be equivalent with those of patients who underwent radical surgery. Limited to stage I disease, there was no recurrence in both patients treated with FSS and in patients treated with radical surgery. However, we observed recurrence following FSS in the patient with stage II MT-MCT due to her hope to preserve fertility. Our results suggest that FSS may be an acceptable choice for patients with stage I MT-MCT but not for those with stage II disease.

As summarized in Table [4](#T4){ref-type="table"}, there was no relapse in a total of 25 patients with stage I disease treated with FSS, therefore, conservative surgery for patients with MT-MCT may be applicable at least for stage I MT-MCT. Although the significance of adjuvant chemotherapy following conservative surgery is not well understood, approximately one-third of patients with stage I MT-MCT received adjuvant chemotherapy following FSS. To maximize fertility preservation, conservative surgery followed by adjuvant chemotherapy may be a reasonable choice. However, we should keep in mind the possibility of the publication bias. Namely, it is unlikely that any surgeon would have report a case in which the patient have recurred and/or died from disease. It is possible that patients who have favorable clinical outcome tends to be reported particularly in a case study.

The limitations of the current report are those associated with any retrospective study, containing a possibility of selection bias, and treatment heterogeneity. Indeed, because our cases were accumulated from multiple institutions over a long time, the treatment protocol for MT-MCT, including the salvage chemotherapy, was not necessarily consistent. Moreover, the most weakness of our current study was based on small-scale patient number due to the fact that experience of patients with MT-MCT was extremely rare. Particularly, in multivariable analysis, including a variety of clinicopathologic indicators, the significance of the residual tumor disappeared as an independent prognostic factor (HR: 0.76, P= 0.67, 95% CI: 0.21-2.74). Probably, because the stage and residual tumor were strongly correlated with each other, we speculate that the "multicolinearity" might be observed. We also think that it might be related to the small-scale sample number as type II error. In this context, this investigation is a hypothesis-generating study on the application and expectable effect of FSS in young women with MT-MCT. We would like to reevaluate the results of the current examination in other future study, accumulating more and more patients with MT-MCT.

In conclusion, although the criteria for FSS for early stage MT-MCT is not well established, FSS may be an alternative to radical surgery for women of child-bearing age with early-stage MT-MCT at childbearing age. We only report that the prognosis of patients with early-stage MT-MCT who underwent FSS may be not inferior to that of patients who received radical surgery. Accordingly, FSS for women with MT-MCT should be carefully selected based on comprehensive informed consent of the potential increased risk of recurrence. Further evidences regarding MT-MCT is required to safely suggest FSS for patients who wish to preserve fertility.

PATIENTS AND METHODS {#s4}
====================

Between January 1986 and December 2016, patients with MT-MCT were accumulated by the Tokai Ovarian Tumor Study Group (TOTSG), consisting of Nagoya University Hospital and 13 affiliated institutions cooperating under the central pathological review system. Patients with EOC, malignant germ cell tumors or borderline epithelial tumors were excluded.

We collected and analyzed data from the medical records and clinical follow-up visits, including age, FIGO stage (International Federation of Gynecology and Obstetrics: 1988), type of surgery, tumor histology, tumor marker, adjuvant chemotherapy, date of recurrence, date of operation, date of death or last follow-up and pregnancy outcome. Two patients were excluded from this analysis due to insufficient information regarding surgical procedure and lost to follow-up immediately after operation. Histological slides were reexamined by our central pathological review system with no knowledge of the patients' data.

The surgical management plan for patients was determined by staging at initial surgery. In principle, complete radical surgery including total hysterectomy and bilateral salpingo-oophorectomy with peritoneal staging and lymphadenectomy was performed except for in patients who wished to preserve fertility at the age of \<45 years old or had difficulty in undergoing radical surgery due to complications. In this study, we defined both complete radical surgery as mentioned above and incomplete surgery including total hysterectomy and bilateral salpingo-oophorectomy, as radical surgery. FSS was fundamentally defined as unilateral oophorectomy or cystectomy with or without omentectomy, together with cytology of ascites and evaluation of any suspected metastasis, including lymph nodes and intraperitoneal dissemination by preoperative or postoperative CT scan.

In order to evaluate oncological outcome of early stage MT-MCT, patients with stage I-II MT-MCT were divided into three groups: group A, patients who underwent FSS with eligible criteria as shown below; group B, patients who were less than 45 years old and underwent radical surgery including total hysterectomy and bilateral salpingo-oophorectomy; group C, patients who were more than 46 years old at the initial surgery. Eligible patients for group A were: (1) under 45 years old at the time of the initial surgery, (2) those who strongly desired to retain fertility, (3) were informed of the pros and cons of FSS, and signed a consent form. Following initial treatment, all patients underwent a periodic follow-up, including an ultrasonographic scan and CT scan. The overall survival (OS) was determined by the duration between the date of initial surgery and the last date of follow-up or death due to any reason. Disease-free survival (DFS) was defined as the duration between the date of surgery and that of recurrence or the last follow-up. The clinicopathological features among groups were evaluated by Chi-square tests. Survival curves were drawn using the Kaplan-Meier method and compared with the Log-rank test. Univariate and multivariate analyses were performed with Cox\'s proportional hazard model. A P-value of \<0.05 was defined as significant.
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MT-MCT

:   malignant transformation arising from mature cystic teratoma of the ovary

FSS

:   fertility-sparing surgery

OS

:   overall survival

DFS

:   disease-free survival

EOC

:   epithelial ovarian cancer
